Guide

GLP-1 Insurance Coverage: What Plans Actually Do, and How to Find Out Fast

Coverage is the single largest variable in what a GLP-1 costs you — a covered brand can land near $25 a month against $299 to $449 self-pay, and $50 through the Medicare

Why this page comes before any price comparison

Every cash price on this site — compounded programmes from about $147, brand Zepbound at $299 to $449 — is what you pay when coverage is unavailable or has been refused. Coverage changes the number by an order of magnitude, not a percentage.

The order of operations that saves the most money is therefore: establish coverage, exhaust the appeal if it is refused, and only then compare self-pay routes. Most readers arrive at this category in the opposite order.

The four things to establish, in one call

1. Is the drug on the formulary at all, and at which tier?
2. Is it covered for your indication? This is the one that catches people. Many plans cover semaglutide for type 2 diabetes and exclude the identical molecule for weight management. Ask about the indication explicitly, not the drug name.
3. What are the prior-authorization criteria, in writing?
4. Is there a step-therapy requirement — a cheaper drug you must try and fail first?

Ask for a reference number for the call. Coverage determinations get disputed, and a call reference is the cheapest evidence you will ever collect.

The patterns that decide most outcomes

Indication-based exclusion. Weight-management coverage is excluded far more often than diabetes coverage, for the same molecules. If you have a qualifying comorbidity — type 2 diabetes, obstructive sleep apnoea, established cardiovascular disease — the coverage picture can change entirely, because approved indications now exist for several of those.

Employer carve-outs. Employer-sponsored plans commonly exclude weight-management drugs as a category, and that exclusion is written by the employer rather than the insurer. It is therefore an HR question as much as an insurance one.

Medicare. Federal law excludes weight-loss drugs from Part D. The GLP-1 Bridge demonstration sidesteps that from 1 July 2026 to 31 December 2027 at a flat $50 monthly copay for eligible enrollees. It has a defined end date and the successor BALANCE Model's Part D portion has been delayed indefinitely.

Medicaid. Coverage varies by state, and this is one of the few areas where your state genuinely determines the answer rather than merely colouring it.

What a covered brand actually costs

Where a commercial plan covers a brand GLP-1, out-of-pocket cost commonly lands near $25 a month with a manufacturer savings card applied. That is below every compounded programme in our dataset, for an FDA-approved product with a published trial programme.

Savings cards have eligibility rules that exclude government-insured patients, and they usually have annual caps. Read those before assuming the $25 figure applies to you for twelve months.

If you are refused

A first-level denial is not the end of the process and is frequently overturned. The appeal route is set out in our denial appeal guide, and the single most useful preparation is obtaining the written criteria before you appeal — you are then arguing against a document rather than against a decision.

What we do not do on this page

We do not tell you that you qualify, because eligibility depends on your plan document, your diagnosis codes and your clinical history, none of which a website can see. We do not recommend describing your situation in particular terms to obtain approval — that is both bad advice and, in some framings, fraud.

What we can do is tell you which questions produce a usable answer, and what the published rules are.

Questions readers actually ask